Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients.
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients / G. Baldin, A. Ciccullo, S. Rusconi, A. Capetti, G. Sterrantino, M. Colafigli, G. D'Ettorre, A. Giacometti, M.V. Cossu, A. Borghetti, W. Gennari, C. Mussini, V. Borghi, S. Di Giambenedetto. - In: INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS. - ISSN 0924-8579. - (2019 Sep 12). [Epub ahead of print] [10.1016/j.ijantimicag.2019.09.002]
Long term data on the efficacy and tolerability of lamivudine plus dolutegravir as a switch strategy in a multicenter cohort of HIV1-infected, virologically suppressed patients
S. Rusconi;A. Capetti;M.V. Cossu;
2019
Abstract
Results from clinical trials and observational studies suggest that lamivudine plus dolutegravir could be an effective and tolerated option for simplification in HIV-1 positive patients.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Long-term data on DTG+3TC switch, IJAA 2019.pdf
Open Access dal 02/08/2019
Tipologia:
Pre-print (manoscritto inviato all'editore)
Dimensione
817.33 kB
Formato
Adobe PDF
|
817.33 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
